CTOs on the Move

Boston Public Health Commission

www.bphc.org

 
We are one of the nation`s first health departments and trace our roots back to 1799, when Paul Revere was named Boston`s first health officer. Back then, the board of health was formed to fight a potential outbreak of cholera. Taking innovative strides to save lives, health officials posted signs on lampposts, held meetings and led an early-day public information campaign to reduce deaths due to cholera, a highly preventable disease. Two hundred years later, that tradition of prevention continues through the Boston Public Health Commission. While we are the country`s oldest health department, we pride ourselves on having some ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bphc.org
  • 1010 Massachusetts Ave 6th Floor
    Boston, MA USA 02118
  • Phone: 617.534.5395

Executives

Name Title Contact Details
Puneet Sharma
Chief Technology Officer Profile

Similar Companies

Mirth Corporation

Mirth Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sempre Health

Sempre Health is bringing behavior-based, individualized copays to healthcare. Today, we work with health plans and pharma manufacturers to dynamically adjust copays based on individual adherence and behavior, seamlessly at the point of fill.

Fulcrum Health

Leveraging physical medicine to transform health care.

Apollo Health Street

Apollo Health Street is a Conshohocken, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glytec System

Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes.